Oral Mucositis - Pipeline Review, H2 2016

Date: August 17, 2016
Pages: 90
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OE90B78A925EN
Leaflet:

Download PDF Leaflet

Oral Mucositis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Oral Mucositis - Pipeline Review, H2 2016’, provides an overview of the Oral Mucositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
  • The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects
  • The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Oral Mucositis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Oral Mucositis Overview
Therapeutics Development
Pipeline Products for Oral Mucositis - Overview
Pipeline Products for Oral Mucositis - Comparative Analysis
Oral Mucositis - Therapeutics under Development by Companies
Oral Mucositis - Therapeutics under Investigation by Universities/Institutes
Oral Mucositis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Oral Mucositis - Products under Development by Companies
Oral Mucositis - Products under Investigation by Universities/Institutes
Oral Mucositis - Companies Involved in Therapeutics Development
Aldeyra Therapeutics, Inc.
Cellceutix Corporation
Colby Pharmaceutical Company
Daewoong Pharmaceutical Co., Ltd.
Galera Therapeutics, Inc.
Onxeo SA
Oragenics, Inc.
Otsuka Holdings Co., Ltd.
Soligenix, Inc.
Spectrum Pharmaceuticals, Inc.
Spherium Biomed S.L.
Oral Mucositis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AG-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clonidine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-4419 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-219 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nepidermin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebamipide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-13004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oral Mucositis - Dormant Projects
Oral Mucositis - Discontinued Products
Oral Mucositis - Product Development Milestones
Featured News & Press Releases
Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis
May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol
Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide
Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis
Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis
Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015
Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis
Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015
Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting
Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Oral Mucositis, H2 2016
Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Oral Mucositis - Pipeline by Aldeyra Therapeutics, Inc., H2 2016
Oral Mucositis - Pipeline by Cellceutix Corporation, H2 2016
Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H2 2016
Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Oral Mucositis - Pipeline by Galera Therapeutics, Inc., H2 2016
Oral Mucositis - Pipeline by Onxeo SA, H2 2016
Oral Mucositis - Pipeline by Oragenics, Inc., H2 2016
Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Oral Mucositis - Pipeline by Soligenix, Inc., H2 2016
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
Oral Mucositis - Pipeline by Spherium Biomed S.L., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Oral Mucositis - Dormant Projects, H2 2016
Oral Mucositis - Dormant Projects (Contd..1), H2 2016
Oral Mucositis - Dormant Projects (Contd..2), H2 2016
Oral Mucositis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Oral Mucositis, H2 2016
Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Mucositis - Pipeline Review, H1 2014 US$ 1,500.00 Mar, 2014 · 46 pages
Oral Mucositis - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Oral Mucositis - API Insights, 2015 US$ 1,250.00 Aug, 2016 · 60 pages

Ask Your Question

Oral Mucositis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: